Abstract: Objective  To investigate the current status and hotspots of Mendelian randomization (MR) studies in the field of ischemic stroke (IS), and to provide reference for future research directions, digging directions of drug targets and exploring mechanism.
Methods  The MR related English literature in the field of IS in the Web of Science Core Collection was retrieved up to September 2022. CiteSpace was used for cooperation network analysis among countries, institutions and authors, co-citation analysis of literature, co-occurrence and cluster analysis of keywords. Drug development of biomarkers casually linked to IS was inquired by the PharmSnap Global New Drug Database.
Results  A total of 200 articles were retrieved, and these studies entered a stage of rapid development in 2018. England had 80 articles, with intermediary centrality of 0.37 and 27 cooperation countries, while the US had 63 articles, with intermediary centrality of 0.10 and 21 cooperation countries or territories. All of the above data were in the top three of all countries or territories, making England and the US research centers in this area. China has published 106 articles, only with 16 cooperation countries or territories. Rainer Malik from Germany had published 20 papers, with 552 citation and 25 co-authors, all ranking the first. IL-6 was the only biological factor defined as a cluster label in the keywords clustering graph, and “inflammation” was the second most studied risk factor for IS in the keywords co-occurrence graph in the last three years. Among the 12 biomarkers of IS identified by MR, coagulation factor Ⅺ and lipoprotein (a) were the more promising drug targets and relevant drugs have entered clinical trials phase.
Conclusions  MR studies in the field of IS were carried out mainly in European countries or territories represented by England, the US and China. Inflammatory factors such as IL-6 were major research hotspots, and related studies provided evidence for biomarkers, such as coagulation factor Ⅺ and lipoprotein (a), as drug targets.

Key words: Ischemic stroke; Mendelian randomization analysis; Bibliometrics; Visual analysis; Biomarker

摘要： 目的 探讨缺血性卒中领域孟德尔随机化研究的现状及热点，为该领域未来研究方向、药物靶点挖掘方向和探索机制提供参考。
方法 在Web of Science核心合集中检索截至2022年9月应用孟德尔随机化研究缺血性卒中的相关英文文献，用CiteSpace进行发表文献的合作网络分析（国家、机构、学者）、文献共被引情况分析、关键词共现和聚类分析。利用PharmSnap全球新药数据库查询经孟德尔随机化确定与缺血性卒中具有因果关系的生物标志物的药物研发情况。
结果 检索到文献200篇，相关研究2018年进入快速发展阶段。英国发文量为80篇、中介中心性为0.37、存在合作的国家有27个，美国发文量为63篇、中介中心性为0.10、存在合作的国家有21个，以上数据均位列所有国家的前3位，使英国和美国成为研究中心；中国发文量达到106篇，但仅与16个国家存在合作，相对较少；德国学者Rainer Malik发文20篇、文献共被引次数552次、合作学者25人，均位列第一。关键词聚类图中，IL-6是关键词聚类图中唯一被定义为聚类标签的生物因子，且炎症因素是关键词共现图中近3年研究第二多的缺血性卒中风险因素。应用孟德尔随机化确定的缺血性卒中生物标志物共12个，其中凝血因子Ⅺ和载脂蛋白α是更具潜力的药物靶点且已有相关药物进入临床研究阶段。
结论 缺血性卒中领域的孟德尔随机化研究主要在以英国为代表的欧洲国家、美国和中国开展。IL-6等炎症因素是主要研究热点，且相关研究为凝血因子Ⅺ和载脂蛋白α等生物标志物作为药物靶点提供证据。

关键词: 缺血性卒中; 孟德尔随机化分析; 文献计量学; 可视化分析; 生物标志物